{"Clinical Trial ID": "NCT00201760", "Intervention": ["INTERVENTION 1:", "1st arm Gemcitabine/Cisplatin/Trastuzumab", "\u00b7 Gemcitabine 1000 mg/m2 iv over 30 minutes on days 1 and 8 Cisplatin 30 mg/m2 iv over 90 minutes on days 1 and 8 Trastuzumab 2 mg/kg iv over 30 minutes on days 1, 8 and 15 (if trastuzumab has not been administered in the last 3 weeks, a loading dose of 4 mg/kg iv over 90 minutes will be administered on the first day of cycle 1 only).", "Gemcitabine: 1000 mg/m2 IV over 30 minutes on days 1 and 8.", "Trastuzumab: 2 mg/kg IV on days 1, 8 and 15. If Trastuzumab has not been administered within 3 weeks prior to the start of this treatment, the first dose of Trastuzumab given in Cycle 1, Day 1 will be 4 mg/kg followed by 2 mg/kg per week.", "Cisplatin: 30 mg/m2 IV on day 1 and day 8.", "INTERVENTION 2:", "Bras 2 Gemcitabine / Trastuzumab", "- Gemcitabine 1000 mg/m2 iv over 30 minutes on days 1 and 8 Trastuzumab 2 mg/kg iv over 30 minutes on days 1, 8 and 15 (if trastuzumab has not been administered within the last 3 weeks, a loading dose of 4 mg/kg iv over 90 minutes will be administered on the first day of cycle 1 only).", "Gemcitabine: 1000 mg/m2 IV over 30 minutes on days 1 and 8.", "Trastuzumab: 2 mg/kg IV on days 1, 8 and 15. If Trastuzumab has not been administered within 3 weeks prior to the start of this treatment, the first dose of Trastuzumab given in Cycle 1, Day 1 will be 4 mg/kg followed by 2 mg/kg per week."], "Eligibility": ["\u2022 Eligibility criteria:", "\u2022 Must have invasive metastatic breast cancer", "The tumour must be Sa 2/neu 3+ by IHC (must be confirmed by the pathology of Ohio State University) or positive FISH", "\u00b7 Histological confirmation of invasive breast cancer, either from the initial diagnosis and/or diagnosis of metastatic disease.", "The tumours must be detectable clinically or radiographically (a positive bone scan is allowed as the sole site of the disease).", "There is no evidence of congestive heart failure, coronary artery symptoms, severe cardiac arrhythmias or anterior myocardial infarction on EKG or ECHO. Patients should have normal function of LV and LVEF (left ventricular ejection fraction)> 50%, as demonstrated by the echo or muga during 4 weeks of treatment.", "A serum creatinine < 1.5 x upper institutional limit of normal (LSN), serum bilirubin < 1.5 x ULN and liver enzymes (AST, ALT or alkaline phosphatase) < 2 x ULN (< 5 x ULN if liver metastases) should have adequate renal and hepatic function within 21 days of registration.", "Patients should have an ANC (absolute number of neutrophils) > 1.5 platelets > 100,000 haemoglobin > 9.0 within 21 days of registration.", "If patients are on bisphosphonates at the time of registration, with stable creatinine in the previous 2 months, then they can continue bisphosphonates during the study.", "Additional treatment with Trastuzumab may have been given in an adjuvant setting. Prior hormonal treatment is permitted for adjuvant or metastatic diseases.", "Previous trastuzumab may have been administered within one week of initiation of treatment if the last dose was 2 mg/kg. Any previous administration of trastuzumab greater than 2 mg/kg requires a 3-week washing period.", "Patients may already have received cisplatin or carboplatin for metastatic disease.", "No CNS metastases (central nervous system).", "No active infection at the time of registration.", "Pregnant or lactating women may not participate in the trial.", "Patients should be informed of the experimental nature of this study and sign and give written informed consent in accordance with institutional and federal guidelines.", "ECOG (Eastern Cooperative Oncology Group) performance status < 2 at the time of registration.", "Patients may participate in a non-treatment-related protocol while participating in this study.", "No other active malignancy is permitted.Basal cell adequately treated, skin cancer of squamous cells, cervical cancer in situ, properly treated stage I or II cancer whose patient is currently in full remission, or any other cancer whose patient has been free of disease for 5 years is allowed."], "Results": ["Performance measures:", "Progression of the disease", "Proportion of patients with metastatic breast cancer without disease progression at 6 months after treatment", "Time limit: 6 months", "Results 1:", "Title of arm/group: Arm 1 Gemcitabine/Cisplatinum/Trastuzumab", "Description of the arm/group: Gemcitabine 1000 mg/m2 iv over 30 minutes on days 1 and 8 Cisplatin 30 mg/m2 iv over 90 minutes on days 1 and 8 Trastuzumab 2 mg/kg iv over 30 minutes on days 1, 8 and 15 (if trastuzumab has not been administered over the last 3 weeks, a loading dose of 4 mg/kg iv over 90 minutes will be administered on the first day of cycle 1 only).", "Gemcitabine: 1000 mg/m2 IV over 30 minutes on days 1 and 8.", "Trastuzumab: 2 mg/kg IV on days 1, 8 and 15. If Trastuzumab has not been administered within 3 weeks prior to the start of this treatment, the first dose of Trastuzumab given in Cycle 1, Day 1 will be 4 mg/kg followed by 2 mg/kg per week.", "Cisplatin: 30 mg/m2 IV on day 1 and day 8.", "Total number of participants analysed: 5", "Type of measure: Number of participants", "Unit of measure: Participants 1 20.0%", "Results 2:", "Title of arm/group: Arm 2 Gemcitabine / Trastuzumab", "Description of the arm/group: Gemcitabine 1000 mg/m2 iv over 30 minutes on days 1 and 8 Trastuzumab 2 mg/kg iv over 30 minutes on days 1, 8 and 15 (if trastuzumab has not been administered over the last 3 weeks, a loading dose of 4 mg/kg iv over 90 minutes will be administered on the first day of cycle 1 only).", "Gemcitabine: 1000 mg/m2 IV over 30 minutes on days 1 and 8.", "Trastuzumab: 2 mg/kg IV on days 1, 8 and 15. If Trastuzumab has not been administered within 3 weeks prior to the start of this treatment, the first dose of Trastuzumab given in Cycle 1, Day 1 will be 4 mg/kg followed by 2 mg/kg per week.", "Total number of participants analysed: 5", "Type of measure: Number of participants", "Unit of measure: Participants 0 0.0%"], "Adverse Events": ["Undesirable Events 1:", "Total: 1/5 (20.00 per cent)", "Nausea/vomiting/diarrhoea 1/5 (20.00 %)", "Pneumonia 1/5 (20.00 %)", "Adverse Events 2:", "Total: 0/5 (0.00 per cent)", "Nausea/vomiting/diarrhoea 0/5 (0.00 %)", "Pneumonia 0/5 (0.00 %)"]}